Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL

Kanutte Huse, Yngvild Blaker, Jillian Frances Wise, Ankush Sharma, Leo Meriranta, Kathrine Thuestad Isaksen, Ivana Spasevska, Sigve Nakken, Vera Hilden, Mette Førsund, Sirpa Leppä, Erlend B. Smeland, Harald Holte, June Helen Myklebust

Blood (2023) 142 (Supplement 1): 179.

https://doi.org/10.1182/blood-2023-189098

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Suvi-Katri Leivonen, Kristiina Karihtala, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 4386.

https://doi.org/10.1182/blood-2023-173117

Published: 2023

Journal Articles

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Matias Autio, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 178.

https://doi.org/10.1182/blood-2023-177893

Published: 2023

Journal Articles

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Blood (2023) 142 (Supplement 1): 176.

https://doi.org/10.1182/blood-2023-182294

Published: 2023

Journal Articles

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Judit Mészáros Jørgensen, Harald Holte, Øystein Fluge, Peter de Nully Brown, Kristina Drott, Sirkku Jyrkkiö, Suvi-Katri Leivonen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2023-177849

Published: 2023

Journal Articles

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2023-188493

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Suvi-Katri Leivonen, Terhi Friman, Samuli Vaittinen, Andreas Wind Jensen, Francesco Annibale d'Amore, Stephen Jacques Hamilton-Dutoit, Harald Holte, Klaus Beiske, Panu Kovanen, Riikka Räty, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 6434–6435.

https://doi.org/10.1182/blood-2022-155860

Published: 2022

Journal Articles

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3500–3503.

https://doi.org/10.1182/blood-2022-168002

Published: 2022

Journal Articles

Tumor Microenvironment and It's Prognostic Value Is Different in Testicular and Systemic Diffuse Large B-Cell Lymphoma

Marjukka Pollari, Matias Autio, Oscar Brück, Teijo Pellinen, Suvi-Katri Leivonen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 3573–3574.

https://doi.org/10.1182/blood-2022-156042

Published: 2022

Journal Articles

The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma

Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 3568–3569.

https://doi.org/10.1182/blood-2022-158431

Published: 2022

Journal Articles

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Blood (2022) 140 (Supplement 1): 3559–3561.

https://doi.org/10.1182/blood-2022-169476

Published: 2022

Journal Articles

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Leo Meriranta, Selma Sorri, Sadia Zafar, Xiaonan Liu, Eerika Sahlberg, Olli Dufva, Helka Göös, Marja-Liisa Karjalainen-Lindsberg, Markku Varjosalo, Marko Hyytiäinen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 5889–5890.

https://doi.org/10.1182/blood-2022-166768

Published: 2022

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Karin Fahl Wader, Ingrid Glimelius

Blood (2022) 140 (Supplement 1): 184–185.

https://doi.org/10.1182/blood-2022-155654

Published: 2022

Journal Articles

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Blood (2022) 140 (Supplement 1): 1768–1769.

https://doi.org/10.1182/blood-2022-158183

Published: 2022

Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Blood (2022) 140 (Supplement 1): 1464–1466.

https://doi.org/10.1182/blood-2022-158203

Published: 2022

Journal Articles

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Harald Holte, Judit Jørgensen, Peter De Nully Brown, Sirkku Jyrkkio, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Matias Autio, Suvi-Katri Leivonen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 1316–1317.

https://doi.org/10.1182/blood-2022-158426

Published: 2022

Journal Articles

Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study

Ilja Kalashnikov, Tomas Tanskanen, Leevi Viisanen, Nea Malila, Sirkku Jyrkkio, Sirpa Leppä

Blood (2022) 140 (Supplement 1): 9345–9346.

https://doi.org/10.1182/blood-2022-170380

Published: 2022

NARROW

Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Tumor Microenvironment and It's Prognostic Value Is Different in Testicular and Systemic Diffuse Large B-Cell Lymphoma

The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only